1853results about "Germ cells" patented technology

The invention provides an enhancer RNA (Ribonucleic Acid) molecule MZGAe1 and application thereof, and relates to the technical field of biology. The invention provides an enhancer RNA (Ribonucleic Acid) molecule MZGAe1. The nucleotide sequence of the enhancer RNA molecule MZGAe1 is as shown in SEQ ID NO: 1; meanwhile, the invention further provides a specific sgRNA sequence for activating the molecule in a targeted manner and a recombinant vector of the specific sgRNA sequence. Expression of endogenous MZGAe1 of cells is specifically activated by adopting a CRISPR activation technology, and conversion of mouse embryonic stem cells to bicellular-like cells can be efficiently promoted. By providing a brand-new endogenous targeted MZGAe1 accurate activation tool, the efficient transformation of wild mouse embryonic stem cells to bicellular cells can be realized only under the condition of endogenous activation of single enhancer RNA molecule MZGAe1, the proportion is at least increased by 5%, the expression of a totipotent marker gene ZSCAN4 is activated, and the expression of the totipotent marker gene ZSCAN4 is promoted. And an efficient and specific brand-new research tool and scheme are provided for researching zygote genome activation, embryonic development early events and cell reprogramming.

Methods, compositions and devices characterized by in vitro maturation of oocytes. In particular, the present disclosure features methods of inducing oocyte maturation in vitro by co-culturing oocytes of a female subject with an ex vivo composition comprising a plurality of ovarian supporting cells (e.g., granular cells). Additional methods of administering a follicle triggering agent and extracting oocytes from a female subject are also provided. Such methods, compositions, and devices are particularly useful for assisted reproductive technology (ART) procedures.

The invention relates to the technical field of cell differentiation and the technical field of myocardial tissue regenerative medicine, in particular to a method for rapidly inducing directional differentiation of embryonic stem cells into myocardial cells in vitro. A matrix sandwich method is adopted, specific small molecule compounds are added in different time periods to induce the embryonic stem cells to differentiate towards the myocardial cells, and nearly 80% of myocardial cells can be obtained on the seventh day of induced differentiation. Compared with a traditional in-vitro myocardial differentiation induction scheme, the induced differentiation method provided by the invention has the advantages that the variety of related small molecules is few, the dosage is low, the induced differentiation time can be effectively shortened from 15 days to 7 days, the induced differentiation cost is saved, and the method is suitable for large-scale popularization and application. A novel way which is more economical, simpler, more convenient, more stable and more efficient is provided for the production of the stem cell-derived myocardial cells; the cardiac muscle cells obtained by induced differentiation are relatively high in purity and relatively wide in application prospect, and are of great significance to research on drug screening, myocardial regenerative medicine and cardiac developmental biology.

An optical arrangement receives output light emanating from an object disposed within a fluid column that crosses an optical refraction boundary of the fluid column between the object and the optical arrangement. The optical arrangement modifies the output light such that the modified output light has an intensity that is more uniform than the output light.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.

The invention discloses hydrogel for 3D culture of stem cells / organoids and a preparation method of the hydrogel, and belongs to the technical field of biological materials. The hydrogel for 3D culture of stem cells / organoids is formed by a four-arm polyethylene glycol macromolecular polymer, the polyethylene glycol macromolecular polymer has a maleimide group (PEG-4MAL) at each terminal, is coupled with an adhesive peptide containing cysteine, and is obtained by cross-linking with mercapto polyethylene glycol (PEG-SH). The hydrogel is beneficial to organoids, the stem cells are high in growth rate and short in culture period, and the obtained organoids are high in maturity, uniform in size, high in bionic capacity and high in application value. Therefore, the prepared novel hydrogel material provides a more ideal microenvironment for culture of cells and organoids, and promotes application and development of regenerative medicine and tissue engineering.

The invention discloses a high-temperature-resistant klebsiella pneumoniae phage, a composition of the high-temperature-resistant klebsiella pneumoniae phage and a kit, the high-temperature-resistant klebsiella pneumoniae phage is klebsiella pneumoniae phage P6AKPJS20, the preservation number of the high-temperature-resistant klebsiella pneumoniae phage is CCTCC (China Center For Type Culture Collection) NO: M20242965, and the high-temperature-resistant klebsiella pneumoniae phage has a nucleotide sequence as shown in SEQ ID No.1-6. The bacteriophage has broad-spectrum bactericidal ability, wide acid-base tolerance range and certain tolerance to chloroform and diethyl ether, and can still maintain high activity while splitting target bacteria; meanwhile, the bacteriophage has good tolerance to high temperature and can adapt to various application conditions in production.

The invention discloses a pig sperm specific antibody. The coding sequence of the antibody is shown as any one of SEQ ID No: 1-3. According to the method, the nano antibody library is prepared by immunizing alpaca with whole pig sperms, and then the antibody capable of being specifically combined with the X or Y sperms can be screened out through the library, so that sorting of the X and Y sperms is realized. The screened antibody is a nano antibody, the size of the nano antibody is only 10% of that of a traditional antibody, the structure is simpler, the advantages of high stability, strong specificity and low immunogenicity are achieved, large-scale expression of the antibody can be achieved, the production cost of the antibody is greatly reduced, and industrial application is facilitated.

The invention belongs to the technical field of stem cell exosome preparation, and provides a preparation method and therapeutic application of a stem cell exosome loaded with therapeutic molecules, and the preparation method comprises the following steps: S1, selecting and culturing a stem cell line with exosome secretion capability; s2, in the stem cell culture process, adding selected therapeutic molecules, so that the therapeutic molecules can be taken by the stem cells and integrated into exosomes of the stem cells; s3, collecting stem cell culture supernate, and separating and purifying the exosome through a differential centrifugation, ultrafiltration or density gradient centrifugation method; s4, identifying the exosome obtained by separation; a stem cell line with efficient exosome secretion capacity is selected and cultured, and selected therapeutic molecules are added in the culture process, so that efficient loading of the therapeutic molecules is realized; according to the method, the operation steps are simplified, the loading efficiency is improved, it is ensured that therapeutic molecules can be stably integrated into the stem cell exosome, and meanwhile the biological activity and stability of the exosome are kept.

The present teachings provide for a method of breeding livestock in vitro. Provided are steps to create embryonic stem cells from a plurality of blastocysts, genotype the embryonic stem cells to select the best embryos for mating to create offspring, and induce the embryonic stem cells into primordial germ cell-like cells (PGCLCs). Male PGCLCs are further induced into spermatogonial stem cell-like cells, and then spermatid-like cells. Female PGCLCs are induced into oocytes, which are then matured. The resulting gametes can then be mixed with each other or with opposite sex gametes from animals with desirable genetics to create the next generation of embryos, which can then be run through the process again. This method of in vitro breeding can be used to increase the speed of genetic progress in livestock.

The invention provides a method for constructing a chronic unpredictable negative stress model, the chronic unpredictable negative stress model and application of the chronic unpredictable negative stress model in mental disease research, and belongs to the field of brain organ in-vitro model construction. Through dual verification of a microelectrode array and single cell sequencing, an in-vitro brain organ model capable of simulating chronic unpredictable negative stress core characteristics is successfully constructed, and a potential neural network function reconstruction mechanism and a cell molecule basis of the in-vitro brain organ model are disclosed. The comprehensive research normal form breaks through the limitation of a traditional single technology platform, and an accurate and efficient innovative research platform highly related to human is provided for pathogenesis research of mental diseases, especially chronic stress related diseases such as depression and anxiety and development of novel treatment strategies.

The invention belongs to the field of stem cell biology, and relates to pedigree specific differentiation of human pluripotent or embryonic stem cells, in particular to a mesenchymal stem cell induced differentiation culture medium and application thereof. The mesenchymal stem cell induced differentiation culture medium is used for directly inducing and differentiating human induced pluripotent stem cells / or embryonic stem cells into mesenchymal stem cells, the culture medium comprises a mesenchymal stem cell basic culture medium and an additive, and the additive comprises the following components: 2-10 [mu] M of a TGF-beta inhibitor, 2-10 [mu] M of a GSK3 beta inhibitor and 5-10 [mu] M of a Rock inhibitor. By adopting the induced differentiation culture medium provided by the invention, human induced pluripotent stem cells / or embryonic stem cells can be directly induced and differentiated into mesenchymal stem cells, and the obtained mesenchymal stem cells have the advantages of infinite sources, stable quality, high homogeneity and the like; and the human induced pluripotent stem cells / or embryonic stem cells can be directly and directionally differentiated into the mesenchymal stem cells in a relatively short time, so that the culture time is shortened, and the production cost is reduced.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating the genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or component or transcriptional regulator of the MHC-I or MHC-II complex, at least one genetic modification that increases the expression of at least one polynucleotide that encodes a tolerogenic factor, and optionally at least one genetic modification that increases or decreases the expression of at least one gene that encodes a survival factor.

The invention belongs to the technical field of biological medicines, and particularly relates to a preparation for optimizing a sperm function through an extracellular vesicle way, a preparation method and application of the preparation to a sperm injury repair system. The method comprises the following steps: step 1, constructing plasmids; step 2, transfecting cells and constructing a cell line; and step 3, separating the exosome. The method for constructing the plasmid in the step 1 comprises the following steps: firstly, amplifying an SKAP2-CDS sequence from a PCR (Polymerase Chain Reaction) of cDNA; and inserting the SKAP2-CDS sequence into a PHY-GFP plasmid between a BamHI site and an EcoRI site, so as to obtain a recombinant plasmid. According to the invention, the influence of seminal plasma extracellular vesicle protein on sperm functions is used for reference, an exosome transformation technology is adopted, the key protein SKAP2 in seminal plasma extracellular vesicles is expressed into the engineering exosome, sperm motility, capacitation and acrosome reaction can be effectively improved by adding and culturing in vitro sperms, and sperm functions are improved.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating the genetically modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or component or transcriptional regulator of the MHC-I or MHC-II complex, at least one genetic modification that increases the expression of at least one polynucleotide that encodes a tolerogenic factor, and optionally at least one genetic modification that increases or decreases the expression of at least one gene that encodes a survival factor.

An object of the present invention is to provide a cell population suitable for transplant of retinal tissue and a method of production thereof. The present invention provides a cell population for transplant, comprising retinal cells with a modified bipolar cell-regulating gene and a method of production thereof.

The present invention relates to a modified stem cell and an ex vivo method for preparing defined mature cells from genetic programming of said modified stem cell which can be carried out in absence of certain growth factors, as well as a kit allowing to transform stem cells, and the different uses of the mature cells, for example for in vitro drug screening and toxicology or as cultivated meat. The genetic programming involves a molecular switch between two mutually exclusive programs of stem cell expansion and differentiation. The invention may be used for stem cells or other progenitors cells of any type, from any eukaryotic organism, but finds particular application in pluripotent stem cells from humans and livestock animals.

The invention provides a human pluripotent stem cell single cell cloning method and a culture medium thereof, and belongs to stem cell culture. A single cell is inoculated into a 96-hole or 384-hole culture plate by utilizing a limited dilution technology, and meanwhile, the proliferation process of the single cell is tracked and recorded in real time by virtue of a living cell analysis system, so that the obtained clone is ensured to be derived from the single cell. According to the method provided by the invention, a large number of clone groups derived from single cells can be simply, conveniently, quickly and easily obtained, and a solid foundation is laid for future large-scale production and industrial technical platforms.

The present invention relates to pluripotent stem cell comprising an expression construct for expression of a Myo1B protein. The invention further provides for methods of producing adipocytes comprising the pluripotent stem cells and for foodstuff comprising the adipocytes or pluripotent stem cells.

The invention provides preparation, sorting and application of LGE / CGE organoid and GABAergic neurons, and belongs to the field of brain organoid differentiation and GABAergic neurons. The preparation method of the LGE / CGE type organ comprises the following steps: S1, performing embryoid formation and initial culture on the 0th-4th day; s2, performing nerve induction and matrigel embedding on the 5th-11th day; s3, culturing the brain organoid on the 12th day to the 19th day; s4, dynamically culturing and screening the brain organoid on the 20th-35th day; and S5, carrying out differentiation and collection on LCOs of the LGE / CGE type organs after the 35th day. According to the method, the LGE / CGE organs containing the high-purity GABA energy neurons are obtained through differentiation from the brain organs for the first time, the high-purity LGE type GABA energy neurons and the high-purity CGE type GABA energy neurons are obtained through a specific sorting method, and the method has the deep application potential in the fields of disease model construction, medicine research and development and the like.

The invention belongs to the technical field of medicines, and discloses application of exosomes derived from human pluripotent stem cells in preparation of anti-hepatic inflammation medicines. According to the invention, the exosome derived from the human pluripotent stem cells is applied to the preparation of the anti-hepatic inflammation medicine, especially the preparation of the anti-hepatic fibrosis anti-inflammatory medicine. The human embryonic stem cell-derived exosome can inhibit and regulate polarization of liver macrophages, inhibit inflammatory liver macrophages, up-regulate anti-inflammatory liver macrophages, reduce secretion of inflammatory factors, improve secretion of anti-inflammatory factors and inhibit liver inflammations and development thereof, has an obvious anti-inflammatory treatment effect on inflammation of liver fibrosis, and can be used for preparing medicines for treating liver fibrosis. Therefore, the progress of hepatic fibrosis can be inhibited.

The invention discloses a biconvex crystalline lens organ relying on stiffness-controllable hydrogel external directional induction as well as a construction method and application thereof. A crystalline lens organ model provided by the invention is jointly realized by virtue of stiffness-controllable hydrogel and a composite growth factor; and the pluripotent stem cells are rapidly and directionally induced into crystalline lens organs with high quality in vitro. According to the technical scheme, the method comprises the following steps: (1) directionally inducing and differentiating the pluripotent stem cells into primary ectoderm cell clusters; (2) preparing hydrogel with specific rigidity and carrying out surface cell adhesion treatment; (3) planting the primary ectoderm cells on the cleaned polyacrylamide hydrogel and inducing the primary ectoderm cells into a neural ectoderm cell cluster; and (4) inducing the neural ectoderm cells to directionally differentiate into mature crystalline lens organs. The three-dimensional lens organ-like model obtained by the method has a sphere-like biconvex morphology with a top surface and a bottom surface, is transparent and has structures such as capsule membranes, lens epithelial cells and lens fibrocytes, and the bottom surface is also wrapped by a complete lens capsule membrane. Compared with the prior art, the method realizes the formation of a complete capsule film on the bottom surface and a sphere-like form. The obtained crystalline lens organ can be used for research on crystalline lens embryonic development, research on cataract pathogenesis and research, development and screening of cataract drugs.

The invention relates to bovine trophoblast stem cells and application thereof.

The invention relates to the technical field of biology, in particular to a composition for preparing a brain organ, the brain organ and application of the brain organ. The invention further discloses a construction method of the brain organ, and on the basis of the method, different stem cells such as ESCs and iPSCs can be utilized to stably construct the three-dimensional brain organ model capable of simulating the medulla oblongata trigeminal nerve. The invention further discloses an organoid assembly which has important application potential in the fields of research on development, functions and related diseases of brain nuclei, drug discovery and the like.

The present technology relates to a systems for quantifying rheotaxis in a sperm-containing sample. The system includes a microfluidic system having an inlet for charging fluids into a passage. One or more probes defining a confinement region suitable for retaining motile sperm are within the passage. The system further comprises an image processing computing device for obtaining a sequence of images of the confinement region of at least one of the one or more probes having motile sperm retained therein. The sequence of images of the confinement region is processed to determine a signal intensity value for said sequence of images, wherein said signal intensity value is based on a concentration of the motile sperm located in the confinement region at the flow rate. A rheotaxis quality value is determined for said sperm-containing sample based on the signal intensity value. Methods for quantifying rheotaxis in a sperm-containing sample are also disclosed.

Provided are compositions and methods for increasing the amount of pro-meiotic proteins in a cell, wherein the proteins are selected from: STRA8, MEIOSIN, DAZL, DMRT1, NANOS3, DDX4, CTCFL, DEK, YY2, SMC1B, or a combination thereof. In some embodiments, the pro-meiotic proteins are useful for inducing meiosis in cells (e.g., non-meiotic cells).

Disclosed herein are universal donor stem cells and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming the immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor stem cells disclosed herein do not express one or more MHC-I and MHC-II human leukocyte antigens. Similarly, in certain embodiments, the universal donor stem cells disclosed herein do not express one or more human leukocyte antigens (e.g., HLA-A, HLA-B and / or HLA-C) corresponding to MHC-I and MHC-II human leukocyte antigens, thereby rendering such cells hypoimmunogenic.